
Avantor, Inc. (NYSE:AVTR – Free Report) – Equities researchers at Zacks Research upped their FY2026 EPS estimates for Avantor in a research note issued on Wednesday, August 19th. Zacks Research analyst Team now forecasts that the company will earn $0.80 per share for the year, up from their previous estimate of $0.78. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Avantor’s current full-year earnings is $0.81 per share. Zacks Research also issued estimates for Avantor’s Q4 2026 earnings at $0.22 EPS, Q1 2027 earnings at $0.18 EPS, Q2 2027 earnings at $0.22 EPS, Q3 2027 earnings at $0.22 EPS, FY2027 earnings at $0.85 EPS, Q2 2028 earnings at $0.23 EPS and FY2028 earnings at $0.92 EPS.
Avantor (NYSE:AVTR – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The company had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same quarter last year, the firm earned $0.24 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS.
View Our Latest Analysis on Avantor
Avantor Stock Performance
AVTR stock opened at $13.97 on Thursday. The stock’s 50 day simple moving average is $11.44 and its 200 day simple moving average is $9.59. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. Avantor has a 12-month low of $7.26 and a 12-month high of $15.93. The stock has a market capitalization of $9.45 billion, a PE ratio of -16.63, a price-to-earnings-growth ratio of 10.04 and a beta of 0.89.
Hedge Funds Weigh In On Avantor
Several hedge funds and other institutional investors have recently modified their holdings of AVTR. Private Trust Co. NA boosted its stake in shares of Avantor by 46.2% in the 4th quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock worth $32,000 after buying an additional 875 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Avantor by 28.1% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,123 shares of the company’s stock valued at $49,000 after acquiring an additional 905 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Avantor by 60.9% in the second quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after acquiring an additional 1,064 shares during the period. UMB Bank n.a. lifted its holdings in Avantor by 17.6% in the fourth quarter. UMB Bank n.a. now owns 7,371 shares of the company’s stock valued at $84,000 after acquiring an additional 1,101 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in Avantor by 119.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after purchasing an additional 1,189 shares during the last quarter. 95.08% of the stock is owned by institutional investors.
Trending Headlines about Avantor
Here are the key news stories impacting Avantor this week:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to $0.80 from $0.78, FY2027 EPS to $0.85 from $0.84, and FY2028 EPS to $0.92 from $0.91. It also increased estimates for Q2 2027 to $0.22 from $0.19 and Q2 2028 to $0.23 from $0.22, pointing to somewhat improved longer-term earnings expectations.
- Positive Sentiment: The upward revisions support the recent strength in Avantor’s stock, particularly because the FY2027 estimate of $0.85 is above the current-year consensus estimate of $0.81. However, the improvements remain relatively small.
- Neutral Sentiment: Zacks’ “Hold” rating indicates that the firm sees a relatively balanced risk-reward profile. The analyst’s FY2026 EPS forecast of $0.80 is also slightly below the broader consensus estimate of $0.81.
- Neutral Sentiment: Recent coverage also compared Avantor’s year-to-date performance with BrightSpring Health Services and the broader medical sector, potentially drawing attention to AVTR’s relative performance. Is Avantor Outperforming Other Medical Stocks This Year?
- Negative Sentiment: Zacks lowered its Q4 2026 EPS estimate to $0.22 from $0.23 and reduced Q1 2027 EPS to $0.18 from $0.19. It also trimmed Q3 2027 EPS to $0.22 from $0.23, partially offsetting the positive revisions.
About Avantor
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Further Reading
- Five stocks we like better than Avantor
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
